CD19 Knockout Raji Cell Line

Catalog #

82166

$4,800 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

CD19 Knockout Raji Cell Line is a Raji cell line where CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed from Raji cells using CRISPR/Cas9 genome editing.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Product Data Gallery

Genomic sequencing of CD19 in the CD19 Knockout Raji Cell Line.

CD19 Expression in CD19 Knockout Raji Cell Line.

Product Info

Storage and Usage

Citations

Host Cell Line

Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension

Supplied As

Each vial contains ˃1 x 10⁶ cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)

Materials Required But Not Supplied

Name	Ordering Information
Thaw Medium 2	BPS Bioscience #60184

Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

The Raji line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T-cells.

CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed at the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy.

Storage/Stability

Cells will arrive upon dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at [email protected] if the cells are not frozen in dry ice upon arrival.

Growth Media

For best results, the use of validated and optimized media from BPS Bioscience is highly recommended. Other preparations or formulations of media may result in suboptimal performance.  Cells should be grown at 37°C with 5% CO₂. BPS Bioscience’s cell lines are stable for at least 10 passages when grown under proper conditions.  

Media Required for Cell Line Culture
Thaw Medium 2 (BPS Bioscience #60184): RPMI-1640 medium supplemented with 10% FBS and 1% Penicillin/Streptomycin.

Applications

Use as a control in CAR-T or NK co-culture killing assays.

Shipping Temperature

-80°C

Notes

The CRISPR/CAS9 technology is covered under numerous patents, including U.S. Patent Nos. 8,697,359 and 8,771,945, as well as corresponding foreign patents applications, and patent rights.

License Disclosure 
Visit bpsbioscience.com/license for the label license and other key information about this product.  

 Troubleshooting Guide 
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected]

Warnings

Avoid freeze/thaw cycles

Scientific Category

Cancer Therapy Target

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

CD19 Knockout Raji Cell Line

PRODUCTS

SERVICES

RESOURCES

COMPANY